Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ludwig Institute For Cancer Research has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are in 2 distinct art units. This spread suggests that the institute's research covers multiple specialized fields within the broader biotechnology sector. Having 2 different administrative groups review the cases requires a prosecution strategy that accounts for varying standards and prior art landscapes. Practitioners must tailor their approach to the specific requirements of each of the 2 units involved to ensure consistent progress. This distribution across 2 units indicates a breadth of technical subject matter.
2 distinct examiners are reviewing the cases. KELLY, ROBERT M is the busiest with 1 pending office action. This distribution means that the workload is split between different individuals. The institute must navigate the individual styles and interpretations of 2 different people across the 2 units. The prosecution strategy should involve monitoring the feedback from all officials to identify unique challenges in the Biotechnology & Pharmaceuticals sector. Success requires a balanced approach to satisfy KELLY, ROBERT M and the other assigned examiner while managing 2 separate prosecution tracks.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493056 | COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18439380 | Products and Methods for Treatment of Amyotrophic Lateral Sclerosis | KELLY, ROBERT M | — |
| 18493056 | COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18439380 | Products and Methods for Treatment of Amyotrophic Lateral Sclerosis | KELLY, ROBERT M | 1638 | §112Other | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18493056 | COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103Other | Non-Final OA | — | Pending | Oct 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLudwig Institute For Cancer Research has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert M Kelly has the most, with 1 of Ludwig Institute For Cancer Research's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
